Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Pharma
Novartis stands by $5B Pluvicto goal despite EU regulatory setback
Novartis CEO remains committed to Pluvicto and its radioligand approach as potential PSMA bispecific challengers advance.
Angus Liu
Apr 28, 2026 10:10am
Kyowa, Sino Biopharm, Duality—Fierce Pharma Asia
Mar 6, 2026 9:35am
China biotech deals, Shionogi's ALS buy—Fierce Pharma Asia
Jan 9, 2026 3:00am
Pfizer, Akeso, Lilly and more—Fierce Pharma Asia
Nov 14, 2025 8:50am
J&J eyes earlier myeloma treatment with ph. 3 Tecvayli combo win
Oct 16, 2025 8:10am
Sanofi, Trump, VC capital crunch—Fierce Pharma Asia
Aug 8, 2025 9:32am
